Retatrutide Source Evaluation: COA & HPLC Purity Checklist

What Is Retatrutide?

Retatrutide (LY-3437943) is an investigational triple-agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). In other words, it targets all three receptor systems rather than one or two, which is why the research literature often compares it with single-agonist compounds like semaglutide and dual-agonist compounds like tirzepatide. In published analyses, its investigational profile is discussed in relation to metabolic health, blood-sugar regulation, appetite signalling, fat metabolism, and energy expenditure, with glucagon-receptor activation described as a proposed contributor to a higher resting metabolic rate. These are research-literature descriptions of an investigational compound, not therapeutic claims.

In a Phase 2 trial published in the New England Journal of Medicine, retatrutide reported a 24.2% mean body-weight endpoint in the highest study arm over 48 weeks. The pivotal Phase 3 TRIUMPH-1 trial later reported 28.3% mean body-weight change at 80 weeks on 12 mg. On July 23, 2026, Lilly also reported TRIUMPH-2 and TRIUMPH-3 topline results and stated that it plans a U.S. BLA filing in Q1 2027 after completing the CMC package. Retatrutide remains investigational. For a detailed regulatory timeline, see the retatrutide approval status tracker.

Retatrutide is an investigational compound handled strictly for in-vitro laboratory research and not intended for human or veterinary administration. This guide is about source documentation and analytical evidence, not medical dosing or treatment. Ongoing preclinical and clinical research is still defining the full profile of this investigational peptide across obesity and metabolic research settings.

Retatrutide Pen Formats in the Research Literature

This table compares the two prefilled pen formats with archived Janoshik batch records on this site. The 30mg pen carries the longest-running batch record; the 20mg pen carries the highest published pen HPLC figure. Both are referenced strictly in an in-vitro laboratory research context. For regional regulatory framing, see the Retatrutide UAE reference.

UAE Regulatory Landscape for Research Peptides

Understanding the regulatory framework is essential before sourcing any research compound in the UAE. Retatrutide occupies a specific position within this framework that researchers should be aware of.

Research-grade peptides that are clearly labelled for in-vitro laboratory use and are not marketed for human consumption operate within the existing regulatory framework. Retatrutide is not classified as a controlled substance in any UAE jurisdiction. As an investigational compound without regulatory approval from the FDA or any other authority, it falls outside the scope of scheduled pharmaceutical regulations.

This is distinct from approved prescription GLP-1 medications like semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro), which are regulated pharmaceuticals available only through licensed pharmacies with a prescription. In the UAE, interest in GLP-1 medications has grown alongside obesity-management demand and broader attention on newer weight-loss medications. Retatrutide will not be available through clinical channels until after FDA approval and subsequent MoHAP regulatory review.

The requirement is that all materials carry “For Research Use Only” labelling and that no therapeutic claims are made. For a broader overview of peptide legality across jurisdictions, see the peptide legality guide, the Dubai-specific legality brief, the Retatrutide UAE reference, and the UAE, GCC and Lebanon guide hub if the search has regional intent beyond Dubai.

If you need the molecule-level routing layer before reading source documentation, open the Retatrutide Research Hub. It separates mechanism, approval status, published trial design, and trial milestones so this checklist can stay focused on analytical evidence.

What the Documentation for a Retatrutide Batch Should Show

Analytical documentation is the only part of a source that can be checked independently. The criteria below separate a batch with a verifiable record from one with a claim, and each maps to a field a reader can look up.

Third-Party Purity Testing

The single most important indicator is independent purity verification. Look for HPLC (High-Performance Liquid Chromatography) analysis conducted by a third-party laboratory — not an in-house test. A minimum threshold of 99% purity is the working standard for research-grade retatrutide. Janoshik Analytical, an independent Czech laboratory, is the most widely recognised name in the peptide research community, and the archived batch records on this site are its reports.

Certificate of Analysis

A genuine COA is batch-specific, dated, and includes quantitative HPLC data with retention times and peak area percentages. Generic specification sheets or undated documents are insufficient. Each archived batch record is published at /coa/ with the batch number, test date, and complete analytical results. Batch RETP002 reads 99.262% purity. For a field-by-field reading of HPLC purity, assay, LC-MS identity, endotoxin, TFA, and heavy metals, use the Peptide COA Guide.

Format and Handling

Retatrutide appears in several formats in the literature: prefilled pen, lyophilised powder vial, and raw powder. For laboratory work requiring repeatable measurement, prefilled pens remove the reconstitution variable. In Dubai’s climate — where summer temperatures regularly exceed 45°C — temperature exposure is the dominant integrity risk, and insulated, temperature-monitored handling is what preserves peptide integrity in transit and in storage. For a complete breakdown of pen mechanics and hardware limits, see the retatrutide pen guide.

Chain of Documentation

A batch record should be traceable back to the laboratory that produced it, not just reproduced as a screenshot. Check that the report carries the laboratory's own identifiers, that the batch number on the report matches the batch number on the unit, and that the test date precedes the release date. A record that cannot be tied to a named laboratory and a specific batch is not evidence, regardless of the purity figure printed on it.

Prefilled Pen vs Vial: Which Format for Dubai Research?

Format selection directly impacts measurement repeatability, handling risk, and workflow efficiency in the laboratory. The following comparison covers the key variables researchers should evaluate.

For many Dubai-based lab workflows, the prefilled pen format offers stronger measurement repeatability and removes the primary handling variable associated with powder reconstitution. The sealed pen system also holds up better thermally in transit — a significant consideration in the UAE climate.

For detailed guidance on pen mechanics and click-based measurement, see the retatrutide pen guide. For storage references across all formats, see the peptide stability and storage guide.

Retatrutide Weight-Loss Mechanism vs Other GLP-1 Research Context

The key differentiator for retatrutide is its triple-receptor mechanism. Approved GLP-1 medicines and next-generation research compounds vary in the receptors they engage; this comparison is included for literature context, not as clinical substitution or purchase guidance.

• Semaglutide (Ozempic in Dubai / Wegovy): Single receptor (GLP-1 only) — body-weight endpoints reported in separate clinical trials
• Tirzepatide (Mounjaro in Dubai): Dual receptor (GLP-1 + GIP) — body-weight endpoints reported in separate clinical trials
• Retatrutide: Triple receptor (GLP-1 + GIP + glucagon) — 24.2% mean body-weight endpoint in Phase 2 data; TRIUMPH-1 Phase 3 topline: 28.3% at 80 weeks (12 mg, May 21, 2026)

These are separate research datasets, not head-to-head purchasing claims. For a full breakdown of mechanism and published trial-design context, see our Retatrutide vs Tirzepatide vs CagriSema comparison.

Purity Benchmarks in the Archived Batch Records

Purity is the one variable a reader can check without trusting anyone. The four archived Janoshik reports published on this site provide a concrete reference band for what a documented retatrutide batch looks like on paper.

• 30mg pen — batch RETP002: 99.262% HPLC (full record)
• 20mg pen — batch RET-20-C-2604-001: 99.841% HPLC (full record)
• 10mg vial — batch RET-20-V-2604-001: 99.741% HPLC (full record)
• 40mg vial — batch RT-40-V-001: 99.692% HPLC, with an extended sterility panel (full record)

Each report names Janoshik Analytical, carries its own batch identifier and test date, and reports the purity figure against a chromatogram rather than as a standalone number. That combination — named laboratory, specific batch, dated test, quantitative result — is the pattern to look for in any batch record, regardless of who is presenting it.

Red flag: A purity claim with no laboratory named behind it, a report that cannot be tied to a batch number stamped on the unit, or a cropped document that omits the chromatogram. Any of the three means the figure is unverified, not that it is wrong — but unverified is where the evaluation stops.

Reading the Sterility Panel

The retatrutide vial records carry a wider panel than the pen records: bacterial endotoxin, heavy metals (arsenic, cadmium, lead, mercury), and residual TFA, each reported as not detected or within pharmaceutical release limits. Those fields matter for vial formats because the reconstitution step introduces a handling variable that a sealed pen does not have. The Peptide COA Guide walks through each field and what the reported limits mean.

Temperature and Handling in the UAE Climate

Temperature exposure is the dominant integrity risk for peptide material in the Gulf. UAE summer ambient temperatures regularly exceed 45°C, which is well outside the range any peptide stability profile is written for, and exposure is cumulative rather than recoverable.

• Lyophilised material: held refrigerated or frozen until reconstitution — the most stable state.
• After reconstitution: 2–8 °C refrigerated storage is the standard reference condition.
• Usable interval: set by the individual batch stability profile, not by a universal figure.
• Avoid: direct light, repeated freeze-thaw cycling, and any period at ambient Gulf temperatures.

Insulated, temperature-monitored handling in transit is what preserves that profile end to end. Material that has spent an unknown interval at ambient temperature carries an unknown stability position no matter what its batch record showed at release.

Verification Sequence for Research Material

Once a source passes the screen above, the remaining checks are documentary. The sequence below is structured around evidence rather than convenience.

1. Confirm research-only labelling: All retatrutide material must carry “For Research Use Only” labelling. No therapeutic, administration, or clinical claims should appear on packaging or accompanying copy.
2. Match the COA to the unit: Cross-reference the batch number on the pen or vial against the published record. Archived batch records are at /coa/.
3. Read the report, not the headline: Check the chromatogram, retention times, and peak areas behind the purity percentage. The Peptide COA Guide explains each field.
4. Match the format to the lab plan: Review the retatrutide pen guide and stability and storage guide before fixing a format.
5. Confirm handling conditions: Dubai summer ambient temperatures regularly exceed 45°C. Establish the temperature history of the material, not just its release condition.
6. Confirm the channel: Use /contact-verify/ to check that a channel claiming to represent this site actually does.

All material referenced here is handled strictly for in-vitro laboratory research. For the regional regulatory picture, see the Retatrutide UAE reference.

How to Use This Reference

Use the page in this order: understand the compound, read a real batch record, then check format and storage. The linked pages are evidence sources, not shortcuts around the verification steps.

1. Start with the compound: Read the retatrutide compound profile and approval status tracker so the regulatory position is clear before anything else.
2. Open a real batch record: Read RETP002 for the 30mg pen and RET-20-C-2604-001 for the 20mg pen in the COA library to see what a complete report contains.
3. Check the format arithmetic: Use the calculator, pen guide, and clicks guide to understand click counts and total milligrams.
4. Verify any channel: Use contact verification before treating any account or page as connected to this site.

July 23, 2026 TRIUMPH-2 and TRIUMPH-3 update

Eli Lilly reported topline results from two additional Phase 3 retatrutide trials on July 23, 2026. In TRIUMPH-2 (1,152 adults with obesity or overweight and type 2 diabetes; 80 weeks), the company reported mean weight reductions of 12.7% at 4 mg, 19.1% at 9 mg, and 20.8% at 12 mg, with A1C reductions up to 1.6 percentage points. In TRIUMPH-3 (1,949 adults with severe obesity and established cardiovascular disease; 80 weeks), mean weight reduction reached 22.6%. These are company-reported topline findings pending full presentation or publication, not a head-to-head comparison.

Lilly also stated that it plans a U.S. Biologics License Application in Q1 2027 after completing the chemistry, manufacturing, and controls package. Retatrutide remains investigational and no application has yet been approved. Primary source: Eli Lilly, July 23, 2026.